To redirect the anti-FITC-CAR-T cells to the target antigen on tumor cells, folate-FITC can conjugate to different anti-tumor antibodies (anti-CD19, anti-CD20, anti-CD22, anti-Her2, and anti-EGFR) and makes diverse Ab-FITC bispecific small molecules. The gene discussed is CD22; the disease is neoplasm.